I'm LongbridgeAI, I can summarize articles.Sandoz Group AG agreed to a USD 400 million settlement framework to resolve generic drug antitrust pricing claims from 43 US states and territories. Payments begin in 2027 over seven years, with a total estimated cost of USD 450 million including a separate USD 28.5 million indirect reseller settlement. The company admitted no wrongdoing, expects no change to its 2026 guidance, and continues to contest remaining individual opt-out cases.
- Sandoz Group AG reached a settlement framework to resolve remaining US state and territory claims in generic drug antitrust pricing litigation. * Deal covers 43 states and territories; USD 400 million payable over seven years starting 2027, subject to approvals; total about USD 450 million. * Separate indirect reseller class settlement set at USD 28.5 million, pending court approval; no admission of wrongdoing in either agreement. * Company expects no change to full-year 2026 guidance or mid-term outlook; provisions increased to reflect the settlements. * Only remaining US antitrust cases involve individual opt-out plaintiffs; Sandoz continues to contest those claims. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2375804_en) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)